CL2011000589A1 - Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer. - Google Patents
Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.Info
- Publication number
- CL2011000589A1 CL2011000589A1 CL2011000589A CL2011000589A CL2011000589A1 CL 2011000589 A1 CL2011000589 A1 CL 2011000589A1 CL 2011000589 A CL2011000589 A CL 2011000589A CL 2011000589 A CL2011000589 A CL 2011000589A CL 2011000589 A1 CL2011000589 A1 CL 2011000589A1
- Authority
- CL
- Chile
- Prior art keywords
- cancer
- treatment
- pharmaceutical composition
- pyrrolidin
- carboxamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Abstract
LA PRESENTE INVENCIÓN DIVULGA COMPUESTOS DE LA FÓRMULA (I): DONDE X, Y, R1, R2, R3, R4, R5, R6 Y R7 TIENEN LOS SIGNIFICADOS DESCRITOS EN EL PLIEGO DE REIVINDICACIONES; LAS SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS; COMPOSICIÓN FARMACÉUTICA QUE INCLUYE A DICHOS COMPUESTOS, Y EL USO DE DICHA COMPOSICIÓN Y COMPUESTOS EN EL TRATAMIENTO DEL CÁNCER.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9788408P | 2008-09-18 | 2008-09-18 | |
US22563309P | 2009-07-15 | 2009-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011000589A1 true CL2011000589A1 (es) | 2011-08-12 |
Family
ID=41402151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011000589A CL2011000589A1 (es) | 2008-09-18 | 2011-03-18 | Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer. |
Country Status (30)
Country | Link |
---|---|
US (1) | US20100075948A1 (es) |
EP (1) | EP2340021B1 (es) |
JP (1) | JP5658157B2 (es) |
KR (1) | KR101380013B1 (es) |
CN (1) | CN102159207B (es) |
AR (1) | AR073598A1 (es) |
AU (1) | AU2009294673B2 (es) |
BR (1) | BRPI0919325A2 (es) |
CA (1) | CA2734363C (es) |
CL (1) | CL2011000589A1 (es) |
CO (1) | CO6361910A2 (es) |
CR (1) | CR20110099A (es) |
DK (1) | DK2340021T3 (es) |
EC (1) | ECSP11010898A (es) |
ES (1) | ES2398342T3 (es) |
HK (1) | HK1160399A1 (es) |
HR (1) | HRP20130047T1 (es) |
IL (1) | IL211167A0 (es) |
MA (1) | MA32711B1 (es) |
MX (1) | MX2011002976A (es) |
MY (1) | MY160424A (es) |
NZ (1) | NZ591024A (es) |
PE (1) | PE20110367A1 (es) |
PL (1) | PL2340021T3 (es) |
PT (1) | PT2340021E (es) |
RS (1) | RS52660B (es) |
RU (1) | RU2506257C2 (es) |
TW (1) | TWI367207B (es) |
WO (1) | WO2010031713A1 (es) |
ZA (1) | ZA201101740B (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
US8354444B2 (en) * | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
US8017607B2 (en) | 2009-10-14 | 2011-09-13 | Hoffmann-La Roche Inc. | N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions |
US20110118283A1 (en) * | 2009-11-17 | 2011-05-19 | Qingjie Ding | Substituted Pyrrolidine-2-Carboxamides |
US8088815B2 (en) * | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
US20120010235A1 (en) * | 2010-07-12 | 2012-01-12 | Xin-Jie Chu | N-substituted pyrrolidines |
US20120046306A1 (en) * | 2010-08-18 | 2012-02-23 | David Joseph Bartkovitz | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists |
CN101898998B (zh) * | 2010-08-25 | 2012-09-19 | 武汉武药科技有限公司 | 一种盐酸替罗非班中间体的制备方法 |
US20120065210A1 (en) | 2010-09-15 | 2012-03-15 | Xin-Jie Chu | Substituted hexahydropyrrolo[1,2-c]imidazolones |
WO2012076513A1 (en) * | 2010-12-09 | 2012-06-14 | F. Hoffmann-La Roche Ag | 3-cyano-1-hydroxymethyl-2-phenylpyrrolidine derivatives as inhibitors of mdm2-p53 interactions useful for the treatment of cancer |
SG193002A1 (en) | 2011-03-10 | 2013-09-30 | Daiichi Sankyo Co Ltd | Dispiropyrrolidine derivative |
CA2850166C (en) | 2011-09-27 | 2019-12-03 | Amgen Inc. | Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer |
US8993614B2 (en) | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
WO2013178570A1 (en) * | 2012-05-30 | 2013-12-05 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
AU2014223547B2 (en) | 2013-02-28 | 2017-11-16 | Amgen Inc. | A benzoic acid derivative MDM2 inhibitor for the treatment of cancer |
JP6377123B2 (ja) | 2013-03-14 | 2018-08-22 | アムジエン・インコーポレーテツド | 癌の治療のためのmdm2阻害剤としてのヘテロアリール酸モルホリノン化合物 |
JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
CN105378112B (zh) | 2013-07-03 | 2020-10-13 | 豪夫迈·罗氏有限公司 | 用于将用MDM2拮抗剂进行患者癌症治疗个人化的基于mRNA的基因表达 |
WO2015161032A1 (en) | 2014-04-17 | 2015-10-22 | The Regents Of The University Of Michigan | Mdm2 inhibitors and therapeutic methods using the same |
TWI711452B (zh) | 2015-02-20 | 2020-12-01 | 日商第一三共股份有限公司 | 癌症的倂用治療法 |
JP6823587B2 (ja) | 2015-04-13 | 2021-02-03 | 第一三共株式会社 | Mdm2阻害剤とbtk阻害剤との併用治療法 |
GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
US20190240210A1 (en) | 2016-10-17 | 2019-08-08 | Daiichi Sankyo Company, Limited | Treatment Method by Combined Use of MDM2 Inhibitor and DNA Methyltransferase Inhibitor |
KR102122469B1 (ko) | 2016-11-01 | 2020-06-12 | 주식회사 엘지화학 | 변성 공액디엔계 중합체 및 이의 제조방법 |
GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
JOP20200001A1 (ar) | 2017-07-11 | 2022-10-30 | Vertex Pharma | كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم |
WO2019213106A1 (en) | 2018-04-30 | 2019-11-07 | Teva Pharmaceuticals International Gmbh | Solid state forms of idasanutlin |
EP3860654A1 (en) | 2018-10-03 | 2021-08-11 | Rijksuniversiteit Groningen | Photoresponsive nutlin derivatives and uses thereof |
IL293592A (en) | 2019-12-06 | 2022-08-01 | Vertex Pharma | Transduced tetrahydrofurans as sodium channel modulators |
EP4347031A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7491394B2 (en) * | 2001-02-15 | 2009-02-17 | The Board Of Trustees Of The University Of Illinois | Cytotoxic factors for modulating cell death |
TW200404796A (en) * | 2002-08-19 | 2004-04-01 | Ono Pharmaceutical Co | Nitrogen-containing compound |
CA2598690C (en) * | 2005-02-22 | 2011-11-15 | The Regents Of The University Of Michigan | Small molecule inhibitors of mdm2 and uses thereof |
CA2656398A1 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
-
2009
- 2009-09-08 PE PE2011000600A patent/PE20110367A1/es active IP Right Grant
- 2009-09-08 EP EP09782745A patent/EP2340021B1/en active Active
- 2009-09-08 CN CN200980136886.XA patent/CN102159207B/zh active Active
- 2009-09-08 BR BRPI0919325-1A patent/BRPI0919325A2/pt not_active Application Discontinuation
- 2009-09-08 DK DK09782745.5T patent/DK2340021T3/da active
- 2009-09-08 MX MX2011002976A patent/MX2011002976A/es active IP Right Grant
- 2009-09-08 RS RS20130030A patent/RS52660B/en unknown
- 2009-09-08 CA CA2734363A patent/CA2734363C/en active Active
- 2009-09-08 ES ES09782745T patent/ES2398342T3/es active Active
- 2009-09-08 NZ NZ591024A patent/NZ591024A/xx unknown
- 2009-09-08 MY MYPI2011001187A patent/MY160424A/en unknown
- 2009-09-08 KR KR1020117006169A patent/KR101380013B1/ko active IP Right Grant
- 2009-09-08 PT PT97827455T patent/PT2340021E/pt unknown
- 2009-09-08 WO PCT/EP2009/061610 patent/WO2010031713A1/en active Application Filing
- 2009-09-08 AU AU2009294673A patent/AU2009294673B2/en active Active
- 2009-09-08 PL PL09782745T patent/PL2340021T3/pl unknown
- 2009-09-08 JP JP2011527289A patent/JP5658157B2/ja active Active
- 2009-09-08 RU RU2011115111/04A patent/RU2506257C2/ru active
- 2009-09-10 US US12/556,656 patent/US20100075948A1/en not_active Abandoned
- 2009-09-15 TW TW098131076A patent/TWI367207B/zh active
- 2009-09-16 AR ARP090103554A patent/AR073598A1/es unknown
-
2011
- 2011-02-10 CO CO11015847A patent/CO6361910A2/es active IP Right Grant
- 2011-02-10 IL IL211167A patent/IL211167A0/en active IP Right Grant
- 2011-02-21 CR CR20110099A patent/CR20110099A/es unknown
- 2011-03-07 ZA ZA2011/01740A patent/ZA201101740B/en unknown
- 2011-03-15 EC EC2011010898A patent/ECSP11010898A/es unknown
- 2011-03-18 CL CL2011000589A patent/CL2011000589A1/es unknown
- 2011-04-13 MA MA33771A patent/MA32711B1/fr unknown
-
2012
- 2012-02-02 HK HK12100945.2A patent/HK1160399A1/xx unknown
-
2013
- 2013-01-21 HR HRP20130047AT patent/HRP20130047T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011000589A1 (es) | Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer. | |
UY32158A (es) | Derivados heterociclicos y metodos de uso de los mismos | |
CO6290656A2 (es) | Derivados heterociclicos de urea y metodos de uso de los mismos -211 | |
UY30759A1 (es) | Compuestos quimicos | |
ECSP109903A (es) | Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares | |
NI201100130A (es) | Derivados de pirimidin indol para el tratamiento de cáncer. | |
BR112015022643A2 (pt) | inibidores diidro-pirrolpiridinona | |
UY32203A (es) | Amino pirimidinas y su uso en terapia | |
CL2012001821A1 (es) | Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
UY32315A (es) | Compuestos de piperidina y usos de los mismo-596 | |
ECSP109934A (es) | Compuesto - 946 | |
CR11857A (es) | Compuestos pirazolicos 436 | |
CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
UY31860A (es) | Piridinas de tiazolo como inhibidoras de la adn girasa | |
EA201070327A1 (ru) | Катехоламиновые производные и их пролекарства | |
UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
UY35275A (es) | Derivados de aminopirazina | |
UY31864A (es) | Derivados de urea hetericíclica y métodos de uso de los mismos-332 | |
EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
UY31141A1 (es) | Compuestos de piperidina y sus usos | |
CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
UY31865A (es) | Derivados de urea heterocíclicos y métodos para la utilización de los mismos | |
UY32674A (es) | Derivados heterociclicos de la urea y sus metodos de empleo |